OakChart

Genprex Inc

GNPXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

2.29+0.20 (9.57%)
2026-11-12 05:37 CET
Market cap
1.88 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-16.50 USD m
Free cash flow, TTM
-15.56 USD m
EPS diluted, TTM
-158.75
P/E
-
Compare

Price

GNPX against its 20, 50 and 200-day averages
2050200
0.0050.00100.002.1M4.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GNPXclose 2.2920-day 2.0950-day 2.71200-day 18.042.2952w high

97.9% under the 52-week high of 110.00 on 12 Nov 2025. 52-week low 1.71 on 27 Oct 2026. Last 15 sessions, 39.2% high to low

Volume 0.66× normal · the line is the 50-bar volume average

Profile

GNPX
52-week range, 1% of the way up
1.71110

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

Employees13
IPOMar 29, 2018
Beta-0.99
ATR, 14d0.22
Rel volume0.66
Short float15.03%
Insider own0.21%
Inst own1.24%

Snapshot

6 groups

Valuation

Index-
Market Cap1.87M
Enterprise Value-13.28M
Income-16.50M
Sales0.00M
Book/sh29.23
Cash/sh18.52
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees13
IPOMar 29, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.08
P/C0.12
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.77
Current Ratio6.77
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-158.75
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y74.00% 55.62%
Sales past 3/5Y- -
EPS Y/Y TTM93.08%
Sales Y/Y TTM-
EPS Q/Q94.96%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.0.00% -

Ownership

Insider Own0.21%
Insider Trans0.00%
Inst Own1.24%
Inst Trans1.22%
ROA-157.40%
ROE-203.86%
ROIC-111.51%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA209.65%
SMA50-15.35%
SMA200-87.31%
Trades-

Technical

Shs Outstand0.82M
Shs Float0.82M
Short Float15.03%
Short Ratio0.51
Short Interest0.12M
52W High110.00 -97.92%
52W Low1.71 33.92%
Volatility9.00% 9.91%
ATR (14)0.22
RSI (14)48.01
Beta-0.99
Rel Volume0.66
Avg Volume243.18K
Volume161,341

Performance

Perf Week7.01%
Perf Month-8.76%
Perf Quarter-52.98%
Perf Half Y-87.77%
Perf YTD-94.05%
Perf Year-97.43%
Perf 3Y-99.98%
Perf 5Y-100.00%
Perf 10Y-
Recom1.00
Target Price8250.00
Prev Close2.09
Price2.29
Change %9.57%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jan 26, 2021InitiatedNNational SecuritiesBuy$7+205.7%
Apr 29, 2019InitiatedNNoble Capital MarketsOutperform$5+118.3%

Peers

Mkt cap
TickerCompanyMkt cap
IMNNImunon Inc4.04M
CLDICalidi Biotherapeutics Inc2.48M
INOInovio Pharmaceuticals Inc152.51M
TOVXTheriva Biologics Inc7.39M
GNLXGenelux Corp85.06M
CADLCandel Therapeutics Inc705.50M
GOVXGeovax Labs Inc1.10M
ONCYOncolytics Biotech Inc52.48M
PDSBPDS Biotechnology Corp107.11M
MTVAMetaVia Inc9.49M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
LONGNECKER BRENT MDirectorApr 14 '26Sale1.2310120Apr 15 06:50 PM
LONGNECKER BRENT MDirectorApr 14 '26Sale1.238109,157Apr 15 06:50 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 100
  • Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium (PR Newswire) +9.57%
  • Genprex Presents Data Showing Reqorsa Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress (PR Newswire)
  • Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa Gene Therapy in Lung Cancer (PR Newswire) -7.36%
  • Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting (PR Newswire)
  • Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA, in Maintaining Cellular Function During Brain Aging (PR Newswire)
  • Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
  • Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy (PR Newswire) -11.73%
  • Genprex Shares Rise After Collaboration With Roche Diagnostics (InvestorsHub) -20.70%
  • Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies (PR Newswire)
  • Genprex's Reqorsa combo secures Canadian patent for lung cancer (Pharmaceutical Business Review) -5.29%
  • Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer (PR Newswire) -7.08%
  • Genprex to Participate at BIO International Convention 2026 (PR Newswire) +10.95%
  • Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting (PR Newswire) -5.98%
  • Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q32024-11-27-1,353-1,353-4,4000.00-1
2024Q22024-08-28-3,300-3,300-3,3050.000.001
2024Q12024-05-29-4,059-4,059-4,0570.000.001
2023Q42024-03-29-4,389-6,045-4,3890.000.002
2023Q32023-11-29-5,060-4,400-5,898--1
2023Q22023-08-30-5,720-5,720-6,755--1
2023Q12023-05-22-7,040-5,280-8,1850.000.001
2022Q42023-03-31-5,720-5,720-6,1980.000.001
2022Q32022-11-14-5,720-5,720-5,5770.000.001
2022Q22022-08-12-4,840-5,280-4,7490.00-1
2022Q12022-05-13-5,280-5,280-5,2590.00-1
2021Q42022-03-30-5,280-4,400-5,222--2
2021Q32022-02-25-3,080--3,177--1
2021Q22021-11-15-3,520-5,720-3,702--1
2021Q12021-08-13-6,160-5,280-6,270---
2020Q42021-05-17-6,160-12,320-5,3350.000.00-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-39,600-33,440-39,5310.000.00
2019FY-29,187--29,2510.00-
2020FY-22,000-16,720-22,224--
2021FY-18,480-17,600-19,306--
2022FY-22,000--21,7840.00-
2023FY-24,816-26,455-0.9000.000.00
2024FY--4,675-5,872--
2025FY--1,375-382.79--
2026FY--1,265---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2024Q4S2024-05-291000.000.000.00
2024Q4S2024-03-291000.000.000.00
2024Q4S2024-03-221000.000.000.00
2024Q4E2025-02-01100-0.39-0.39-0.39
2024Q4E2024-11-27110-0.39-0.39-0.39
2024Q4E2024-11-18110-0.39-0.39-0.39
2024Q4E2024-08-28100-0.54-0.54-0.54
2024Q4E2024-08-24100-0.54-0.54-0.54
2024Q4E2024-08-12200-0.68-0.82-0.54
2024Q4E2024-07-30100-0.82-0.82-0.82
2024Q4E2024-05-29110-0.82-0.82-0.82
2024Q4E2024-05-16110-0.82-0.82-0.82
2024Q4E2024-04-28110-0.96-0.96-0.96
2024Q4E2024-04-02210-3.28-5.60-0.96

Estimate history

EPS, annual-12405.36-39530.92-29251.2-22224.4-19305.88-21783.96-24819.08-5871.58-382.787-158.7533
Period201720182019202020212022202320242025TTM
EPS, quarterly-3305.071-1356.531-466.675-285.681-186.362-109.901-25.333-14.12-9.399
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0000.0010.0010.0010.0010.010.150.506
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0020.0050.010.0220.030.0460.150.4110.506
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.010.020.030.020.020.010.01
Gross Profit0.000.00-0.01-0.02-0.03-0.02-0.02-0.01-0.01
Selling, General and Administrative Excl. Other15.8415.5221.1731.0623.8120.6517.9410.6712.36
Research and Development9.829.4310.5417.6211.518.977.301.970.97
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-15.84-15.52-21.17-31.08-23.83-20.67-17.96-10.68-12.36
Interest Expense0.000.000.000.000.000.000.000.000.04
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-16.50-16.23-21.11-30.86-23.74-20.66-17.94-10.65-12.37
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-16.50-16.23-21.11-30.86-23.74-20.66-17.94-10.65-12.37
Net Income From Continuing Operations-16.50-16.23-21.11-30.86-23.74-20.66-17.94-10.65-12.37
Net Income-16.50-16.23-21.39-30.86-23.74-20.66-17.94-10.65-12.37
EPS (Recurring)-34.87-382.79-5,871.58-24,819.29-21,783.97-19,305.98-22,224.61-29,251.29-39,531.05
EPS (Basic, Before Extraordinaries)-158.75-382.79-5,871.58-24,819.08-21,783.96-19,305.88-22,224.40-29,251.20-39,530.92
EPS (Diluted)-158.75-382.79-5,871.58-24,819.08-21,783.96-19,305.88-22,224.40-29,251.20-39,530.92
EBITDA-15.84-15.52-21.17-31.06-23.81-20.65-17.94-10.67-12.36
Non-Operating Income (Expense)-0.66-0.710.060.220.090.010.020.030.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.303.105.394.575.194.093.064.88
Shares Outstanding0.510.150.010.000.000.000.000.000.00
Market Capitalization1.881.889.2513.6769.6362.72178.946.1616.76

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00-0.00-0.00
Selling, General and Administrative Excl. Other4.484.493.523.354.683.974.344.32
Research and Development2.682.752.202.192.502.542.842.76
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.48-4.49-3.52-3.35-4.68-3.97-4.34-4.32
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-4.45-4.46-3.79-3.80-4.67-3.96-4.33-4.32
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.45-4.46-3.79-3.80-4.67-3.96-4.33-4.32
Net Income From Continuing Operations-4.45-4.46-3.79-3.80-4.67-3.96-4.33-4.32
Net Income-4.45-4.46-3.79-3.80-4.67-3.96-4.61-4.32
EPS (Recurring)-9.40-14.12-25.33-109.91-186.36-285.69-466.67-1,356.53
EPS (Basic, Before Extraordinaries)-9.40-14.12-25.33-109.90-186.36-285.68-466.68-1,356.53
EPS (Diluted)-9.40-14.12-25.33-109.90-186.36-285.68-466.68-1,356.53
EBITDA-4.48-4.49-3.52-3.35-4.68-3.97-4.34-4.32
Non-Operating Income (Expense)0.040.03-0.27-0.450.010.000.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.070.12-0.020.090.180.300.41
Shares Outstanding0.510.410.150.050.030.020.010.00
Market Capitalization1.8816.375.768.517.555.939.251.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.831.606.7420.9538.6327.322.008.600.16
Short Term Receivables0.000.000.000.030.000.000.000.010.01
Inventories0.000.000.000.000.003.010.800.000.00
Other Current Assets0.530.480.790.480.510.380.170.240.02
Total Current Assets8.362.087.5321.4739.1430.722.988.850.19
Net Property, Plant & Equipment0.000.000.010.020.050.040.040.020.01
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-0.000.770.700.640.600.490.380.30
Other Assets1.802.052.362.893.030.010.020.020.76
Total Assets10.164.1210.6725.0942.8631.373.539.271.26
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.000.000.000.00
Accounts Payable0.741.071.400.440.970.190.440.000.63
Other Current Liabilities1.431.431.862.370.610.260.070.390.20
Total Current Liabilities2.172.503.252.811.590.450.510.390.83
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.020.000.000.000.000.000.000.000.00
Total Liabilities2.202.503.252.811.590.450.510.390.83
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity7.961.627.4222.2741.2830.923.028.880.43
Total Shareholders Equity7.961.627.4222.2741.2830.923.028.880.43
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity7.961.627.4222.2741.2830.923.028.880.43
Total Liabilities & Stockholders Equity10.164.1210.6725.0942.8631.373.539.271.26
Book Value Per Share53.22164.085,490.2820,373.5437,936.2631,549.146,905.9925,642.511,604.19
Tangible Book Value Per Share53.22164.084,917.6819,731.3737,345.8930,935.205,784.0624,546.92486.62
Full-Time Employees13152628171287-
Price to Book Ratio0.085.711.112.531.525.792.041.891.64
Return on Assets-227.24-285.38-172.62-69.88-55.68-102.82-166.44-235.03-209.09
Return on Equity-338.74-467.24-207.88-74.71-57.25-105.73-179.00-265.79-322.79
Return on Invested Capital-203.83-1,303.03-416.11-106.58-50.06-58.04-352.39-139.31-773.30
Quick Ratio3.840.832.317.6424.6961.474.2622.810.23
Current Ratio3.840.832.317.6424.6968.155.8322.810.23

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-16.50-16.23-21.11-30.86-23.74-20.66-17.94-10.65-12.37
Depreciation-0.000.010.020.030.020.020.010.01
Other Funds (Non Cash)0.551.053.305.414.735.354.253.535.44
Funds from Operations-15.94-15.18-17.80-25.44-18.98-15.29-13.67-7.11-6.93
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.38-0.14-0.120.701.201.01-0.260.190.10
Cash from Operating Activities-15.56-15.31-17.92-24.74-17.78-14.28-13.94-6.92-6.83
Capital Expenditures0.000.000.00-0.07-0.06-0.07-0.13-0.15-0.10
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-0.01-2.21-0.800.00
Other Sources0.000.000.770.000.16-0.000.000.00
Cash from Investing Activities0.000.000.77-0.070.10-0.08-2.34-0.95-0.10
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock29.3721.5412.0110.590.0125.6841.591.2715.39
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock29.3721.5412.0110.590.0125.6841.591.2715.39
Proceedsfrom Stock Options29.3721.5412.0110.590.0125.6841.591.2715.39
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities29.3721.5412.0110.590.0125.6841.591.2715.39
Net Change in Cash13.816.23-5.14-14.22-17.6711.3125.32-6.608.46
Free Cash Flow-15.56-15.31-17.92--17.78-14.32-13.95-6.95-6.85
Preferred Dividends (Cash Flow)-0.00-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments15.1518.057.831.101.353.47
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.690.750.530.610.710.70
Total Current Assets15.8418.808.361.722.064.16
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Other Assets1.291.501.801.851.771.85
Total Assets17.1420.3110.163.563.836.01
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.291.660.741.620.931.53
Other Current Liabilities2.051.701.430.931.510.62
Total Current Liabilities2.343.352.172.552.442.14
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.020.020.240.000.00
Total Liabilities2.343.382.202.792.442.14
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity14.8016.937.960.771.393.87
Total Shareholders Equity14.8016.937.960.771.393.87
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity14.8016.937.960.771.393.87
Total Liabilities & Stockholders Equity17.1420.3110.163.563.836.01
Book Value Per Share29.2341.1853.2216.8246.17176.14
Tangible Book Value Per Share29.2341.1853.2216.8246.17176.14
Full-Time Employees--13---
Price to Book Ratio0.080.970.7211.085.431.53
Return on Assets-157.40-127.12-227.24-448.99-331.39-205.73
Return on Equity-203.86-160.84-338.74-1,378.61-602.64-302.69
Return on Invested Capital-30.06-26.35-47.60-494.82-336.03-102.50
Quick Ratio6.775.613.840.670.841.94
Current Ratio6.775.613.840.670.841.94

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.45-4.46-3.79-3.80-4.67-3.96
Depreciation--0.000.000.000.00
Other Funds (Non Cash)0.070.07-0.060.480.460.18
Funds from Operations-4.38-4.39-3.85-3.32-4.22-3.78
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.761.25-0.250.140.36-0.38
Cash from Operating Activities-5.14-3.14-4.10-3.19-3.86-4.16
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.2413.3610.832.941.746.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.2413.3610.832.941.746.03
Proceedsfrom Stock Options2.2413.3610.832.941.746.03
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.2413.3610.832.941.746.03
Net Change in Cash-2.9010.226.73-0.24-2.121.87
Free Cash Flow-5.14-3.14-4.10-3.19-3.86-4.16

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.03%0.1M0.8M281.62K
2026-10-1515.23%0.1M0.8M261.56K
2026-09-3011.84%0.1M0.8M232.61K
2026-09-1510.09%0.1M0.8M174.18K
2026-08-3110.47%0.1M0.8M168.73K
2026-08-147.63%0.1M0.8M84.83K
2026-07-317.38%0.0M0.5M22.37K
2026-07-158.04%0.0M0.5M28.45K
2026-06-308.62%0.0M0.5M29.56K
2026-06-159.21%0.0M0.5M28.43K
2026-05-299.26%0.0M0.5M29.09K
2026-05-159.88%0.0M0.5M41.44K
2026-04-3012.75%0.1M0.4M41.80K
2026-04-155.86%0.0M0.4M37.00K
2026-03-314.50%0.0M0.4M46.82K
2026-03-1321.82%0.0M0.1M45.92K
2026-02-2732.25%0.0M0.1M45.13K
2026-02-1320.71%0.0M0.1M32.77K
2026-01-3023.50%0.0M0.1M32.59K
2026-01-1521.99%0.0M0.1M31.91K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-218-KCurrent report2026-10-21SEC
2026-08-188-KCurrent report2026-08-18SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-04SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-308-KCurrent report2026-07-29SEC
2026-07-148-KCurrent report2026-07-13SEC
2026-06-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-228-KCurrent report2026-06-22SEC
2026-06-188-KCurrent report2026-06-18SEC
2026-06-128-KCurrent report2026-06-10SEC
2026-06-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-268-KCurrent report2026-05-26SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-11SCHEDULE 13G/ASEC
2026-04-308-KCurrent report2026-04-30SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-04-288-KCurrent report2026-04-28SEC
2026-04-218-KCurrent report2026-04-21SEC
2026-04-17PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-04-154Statement of changes in beneficial ownership of securities2026-04-14SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-188-KCurrent report2026-03-18SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-27SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-0400222
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD FIDUCIARY TRUST CO0.71%
HRT FINANCIAL LP0.66%
GEODE CAPITAL MANAGEMENT, LLC0.55%
VANGUARD CAPITAL MANAGEMENT LLC0.33%
Engineers Gate Manager LP0.19%
Mayflower Financial Advisors, LLC0.18%
UBS Group AG0.05%
Tower Research Capital LLC0.03%
BARCLAYS PLC0.01%
JONES FINANCIAL COMPANIES LLLP0.01%

Funds

Fund% owned
Fidelity Extended Market Index Fund1.11%
VANGUARD EXTENDED MARKET INDEX FUND0.05%
Fidelity Series Total Market Index Fund0.01%
Fidelity Total Market Index Fund0.00%
Blackstone Alternative Multi-Strategy Fund-0.01%

OakChart. GNPX. Cached 15 minutes.